Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study
Identifieur interne : 004771 ( Main/Exploration ); précédent : 004770; suivant : 004772Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study
Auteurs : Paolo Del Dotto [Italie] ; Nicola Pavese [Italie] ; Gianna Gambaccini [Italie] ; Silvia Bernardini [Italie] ; Leonard Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Ubaldo Bonuccelli [Italie]Source :
- Movement Disorders [ 0885-3185 ] ; 2001-05.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Amantadine, Amantadine (administration & dosage), Amantadine (therapeutic use), Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Chemotherapy, Dopamine Agents (administration & dosage), Dopamine Agents (therapeutic use), Double blind study, Double-Blind Method, Drug Therapy, Combination, Dyskinesia, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (etiology), Female, Human, Humans, Infusions, Intravenous, Intravenous administration, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors), Receptors, N-Methyl-D-Aspartate (metabolism), Remission Induction, Treatment, amantadine, dyskinesia, levodopa.
- MESH :
- chemical , administration & dosage : Amantadine, Antiparkinson Agents, Dopamine Agents.
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , antagonists & inhibitors : Receptors, N-Methyl-D-Aspartate.
- chemical , metabolism : Receptors, N-Methyl-D-Aspartate.
- chemical , therapeutic use : Amantadine, Antiparkinson Agents, Dopamine Agents, Levodopa.
- complications : Parkinson Disease.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- Aged, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Remission Induction.
Abstract
Experimental evidence suggests that glutamatergic receptor blockade may improve the motor response complications associated with long‐term levodopa treatment in Parkinson's disease (PD) patients. Our objective was to evaluate the acute effect of amantadine, a noncompetitive antagonist of the N‐methyl‐D‐aspartate (NMDA) receptor, on levodopa‐induced dyskinesias, and to gain further insights into the antidyskinetic mechanism of this drug. Nine PD patients with motor fluctuations and severely disabling peak of dose dyskinesias received their first morning levodopa dose, followed by a 2‐hour intravenous amantadine (200 mg) or placebo infusion, on two different days. Parkinsonian symptoms and dyskinesias were assessed every 15 minutes during the infusion and for 3 hours thereafter, while patients were taking their usual oral antiparkinsonian therapy, by means of Unified Parkinson's Disease Rating Scale (UPDRS, motor examination), tapping test, and a modified Abnormal Involuntary Movement Scale (AIMS). Intravenous amantadine acutely improved levodopa‐induced dyskinesias by 50%without any loss of the anti‐parkinsonian benefit from levodopa. This study confirms the antidyskinetic effect of amantadine and strengthens the rationale for using antiglutamatergic drugs in the treatment of parkinsonian motor fluctuations. © 2001 Movement Disorder Society.
Url:
DOI: 10.1002/mds.1112
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002054
- to stream Istex, to step Curation: 002054
- to stream Istex, to step Checkpoint: 002F98
- to stream Main, to step Merge: 006C53
- to stream PascalFrancis, to step Corpus: 002A10
- to stream PascalFrancis, to step Curation: 000311
- to stream PascalFrancis, to step Checkpoint: 002973
- to stream Main, to step Merge: 006E72
- to stream PubMed, to step Corpus: 003D39
- to stream PubMed, to step Curation: 003D39
- to stream PubMed, to step Checkpoint: 003D18
- to stream Ncbi, to step Merge: 000512
- to stream Ncbi, to step Curation: 000512
- to stream Ncbi, to step Checkpoint: 000512
- to stream Main, to step Merge: 006A20
- to stream Main, to step Curation: 004771
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study</title><author><name sortKey="Del Dotto, Paolo" sort="Del Dotto, Paolo" uniqKey="Del Dotto P" first="Paolo" last="Del Dotto">Paolo Del Dotto</name></author><author><name sortKey="Pavese, Nicola" sort="Pavese, Nicola" uniqKey="Pavese N" first="Nicola" last="Pavese">Nicola Pavese</name></author><author><name sortKey="Gambaccini, Gianna" sort="Gambaccini, Gianna" uniqKey="Gambaccini G" first="Gianna" last="Gambaccini">Gianna Gambaccini</name></author><author><name sortKey="Bernardini, Silvia" sort="Bernardini, Silvia" uniqKey="Bernardini S" first="Silvia" last="Bernardini">Silvia Bernardini</name></author><author><name sortKey="Metman, Leonard Verhagen" sort="Metman, Leonard Verhagen" uniqKey="Metman L" first="Leonard Verhagen" last="Metman">Leonard Verhagen Metman</name></author><author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name></author><author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4954DD6BDD4489237BBF9E41A920D61ED0C33275</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/mds.1112</idno><idno type="url">https://api.istex.fr/document/4954DD6BDD4489237BBF9E41A920D61ED0C33275/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002054</idno><idno type="wicri:Area/Istex/Curation">002054</idno><idno type="wicri:Area/Istex/Checkpoint">002F98</idno><idno type="wicri:doubleKey">0885-3185:2001:Del Dotto P:intravenous:amantadine:improves</idno><idno type="wicri:Area/Main/Merge">006C53</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:01-0376775</idno><idno type="wicri:Area/PascalFrancis/Corpus">002A10</idno><idno type="wicri:Area/PascalFrancis/Curation">000311</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002973</idno><idno type="wicri:doubleKey">0885-3185:2001:Del Dotto P:intravenous:amantadine:improves</idno><idno type="wicri:Area/Main/Merge">006E72</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:11391748</idno><idno type="wicri:Area/PubMed/Corpus">003D39</idno><idno type="wicri:Area/PubMed/Curation">003D39</idno><idno type="wicri:Area/PubMed/Checkpoint">003D18</idno><idno type="wicri:Area/Ncbi/Merge">000512</idno><idno type="wicri:Area/Ncbi/Curation">000512</idno><idno type="wicri:Area/Ncbi/Checkpoint">000512</idno><idno type="wicri:doubleKey">0885-3185:2001:Del Dotto P:intravenous:amantadine:improves</idno><idno type="wicri:Area/Main/Merge">006A20</idno><idno type="wicri:Area/Main/Curation">004771</idno><idno type="wicri:Area/Main/Exploration">004771</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study</title><author><name sortKey="Del Dotto, Paolo" sort="Del Dotto, Paolo" uniqKey="Del Dotto P" first="Paolo" last="Del Dotto">Paolo Del Dotto</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neuroscience, Neurology Section, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Pavese, Nicola" sort="Pavese, Nicola" uniqKey="Pavese N" first="Nicola" last="Pavese">Nicola Pavese</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neuroscience, Neurology Section, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Gambaccini, Gianna" sort="Gambaccini, Gianna" uniqKey="Gambaccini G" first="Gianna" last="Gambaccini">Gianna Gambaccini</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neuroscience, Neurology Section, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Bernardini, Silvia" sort="Bernardini, Silvia" uniqKey="Bernardini S" first="Silvia" last="Bernardini">Silvia Bernardini</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neuroscience, Neurology Section, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Metman, Leonard Verhagen" sort="Metman, Leonard Verhagen" uniqKey="Metman L" first="Leonard Verhagen" last="Metman">Leonard Verhagen Metman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neuroscience, Neurology Section, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-05">2001-05</date><biblScope unit="vol">16</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="515">515</biblScope><biblScope unit="page" to="520">520</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">4954DD6BDD4489237BBF9E41A920D61ED0C33275</idno><idno type="DOI">10.1002/mds.1112</idno><idno type="ArticleID">MDS1112</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Amantadine</term><term>Amantadine (administration & dosage)</term><term>Amantadine (therapeutic use)</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Antiparkinson agent</term><term>Chemotherapy</term><term>Dopamine Agents (administration & dosage)</term><term>Dopamine Agents (therapeutic use)</term><term>Double blind study</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Dyskinesia</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Female</term><term>Human</term><term>Humans</term><term>Infusions, Intravenous</term><term>Intravenous administration</term><term>Levodopa</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)</term><term>Receptors, N-Methyl-D-Aspartate (metabolism)</term><term>Remission Induction</term><term>Treatment</term><term>amantadine</term><term>dyskinesia</term><term>levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Amantadine</term><term>Antiparkinson Agents</term><term>Dopamine Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptors, N-Methyl-D-Aspartate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, N-Methyl-D-Aspartate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term><term>Antiparkinson Agents</term><term>Dopamine Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Infusions, Intravenous</term><term>Male</term><term>Middle Aged</term><term>Remission Induction</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Amantadine</term><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Dyskinésie</term><term>Etude double insu</term><term>Homme</term><term>Lévodopa</term><term>Parkinson maladie</term><term>Traitement</term><term>Voie intraveineuse</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Experimental evidence suggests that glutamatergic receptor blockade may improve the motor response complications associated with long‐term levodopa treatment in Parkinson's disease (PD) patients. Our objective was to evaluate the acute effect of amantadine, a noncompetitive antagonist of the N‐methyl‐D‐aspartate (NMDA) receptor, on levodopa‐induced dyskinesias, and to gain further insights into the antidyskinetic mechanism of this drug. Nine PD patients with motor fluctuations and severely disabling peak of dose dyskinesias received their first morning levodopa dose, followed by a 2‐hour intravenous amantadine (200 mg) or placebo infusion, on two different days. Parkinsonian symptoms and dyskinesias were assessed every 15 minutes during the infusion and for 3 hours thereafter, while patients were taking their usual oral antiparkinsonian therapy, by means of Unified Parkinson's Disease Rating Scale (UPDRS, motor examination), tapping test, and a modified Abnormal Involuntary Movement Scale (AIMS). Intravenous amantadine acutely improved levodopa‐induced dyskinesias by 50%without any loss of the anti‐parkinsonian benefit from levodopa. This study confirms the antidyskinetic effect of amantadine and strengthens the rationale for using antiglutamatergic drugs in the treatment of parkinsonian motor fluctuations. © 2001 Movement Disorder Society.</div></front></TEI><affiliations><list><country><li>Italie</li><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="Italie"><noRegion><name sortKey="Del Dotto, Paolo" sort="Del Dotto, Paolo" uniqKey="Del Dotto P" first="Paolo" last="Del Dotto">Paolo Del Dotto</name></noRegion><name sortKey="Bernardini, Silvia" sort="Bernardini, Silvia" uniqKey="Bernardini S" first="Silvia" last="Bernardini">Silvia Bernardini</name><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name><name sortKey="Gambaccini, Gianna" sort="Gambaccini, Gianna" uniqKey="Gambaccini G" first="Gianna" last="Gambaccini">Gianna Gambaccini</name><name sortKey="Pavese, Nicola" sort="Pavese, Nicola" uniqKey="Pavese N" first="Nicola" last="Pavese">Nicola Pavese</name></country><country name="États-Unis"><region name="Maryland"><name sortKey="Metman, Leonard Verhagen" sort="Metman, Leonard Verhagen" uniqKey="Metman L" first="Leonard Verhagen" last="Metman">Leonard Verhagen Metman</name></region><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004771 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004771 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4954DD6BDD4489237BBF9E41A920D61ED0C33275
|texte= Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study
}}
| This area was generated with Dilib version V0.6.23. |  |